Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleIssues and Controversies

How Should the FDA Review Diagnostic Radiopharmaceuticals?

Carol S. Marcus
Journal of Nuclear Medicine June 2018, 59 (6) 868-870; DOI: https://doi.org/10.2967/jnumed.117.200337
Carol S. Marcus
Departments of Molecular and Medical Pharmacology, Radiation Oncology, and Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 59 no. 6 868-870
DOI 
https://doi.org/10.2967/jnumed.117.200337
PubMed 
29025981

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication August 2, 2017
  • Accepted for publication October 6, 2017
  • Published online June 1, 2018.

Article Versions

  • previous version (October 12, 2017 - 04:30).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Carol S. Marcus
  1. Departments of Molecular and Medical Pharmacology, Radiation Oncology, and Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California
  1. For correspondence or reprints contact: Carol S. Marcus, UCLA, 1877 Comstock Ave., Los Angeles, CA 90025. E-mail: csmarcus{at}ucla.edu Guest Editor: David Mankoff, University of Pennsylvania.
View Full Text

Statistics from Altmetric.com

Cited By...

  • 7 Citations
  • 7 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
    Juan Sun, Zhenyuan Huangfu, Jiangtao Yang, Guanglin Wang, Kuan Hu, Mingyuan Gao, Zhiyuan Zhong
    Advanced Drug Delivery Reviews 2022 190
  • Radiotracers for Nuclear Imaging of Reactive Oxygen Species: Advances Made So Far
    Lumei Huang, Zijing Li, Xianzhong Zhang
    Bioconjugate Chemistry 2022 33 5
  • Perspective on How the FDA Should Review Diagnostic Radiopharmaceuticals
    Sally W. Schwarz, Bonnie Clarke
    Journal of Nuclear Medicine 2018 59 6
  • Handbook of Radiopharmaceuticals
    Arkadij Mikhailovich Elizarov
    2020
  • Radiopharmaceutical good practices: Regulation between hospital and industry
    Alain Faivre-Chauvet, Cécile Bourdeau, Mickaël Bourgeois
    Frontiers in Nuclear Medicine 2022 2
  • Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies
    Abbie Hasson, Wen Jiang, Nadia Benabdallah, Peng Lu, Mark S. Longtine, Bradley J. Beattie, Lucy Summer, Hanwen Zhang, Richard L. Wahl, Diane S. Abou, Daniel L.J. Thorek
    Cancer Biotherapy and Radiopharmaceuticals 2023 38 1
  • SNMMI Clinical Trials Network Research Series for Technologists: Introduction
    Sarah Frye, Regan Butterfield, John M. Hoffman
    Journal of Nuclear Medicine Technology 2021 49 4

Article usage

Article usage: October 2017 to April 2025

AbstractFullPdf
Oct 2017496067
Nov 2017227019
Dec 201710108
Jan 201887014
Feb 201871012
Mar 20188907
Apr 2018128023
May 2018123028
Jun 2018194382252
Jul 20183402642
Aug 20181691426
Sep 2018160737
Oct 2018120846
Nov 201875538
Dec 201866222
Jan 2019961546
Feb 201965629
Mar 2019681631
Apr 201960624
May 2019541333
Jun 201926621
Jul 2019621328
Aug 201930529
Sep 201931431
Oct 2019371418
Nov 2019581043
Dec 201928427
Jan 202021227
Feb 202023818
Mar 2020261844
Apr 2020192019
May 2020452240
Jun 2020381719
Jul 20201523
Aug 20208214
Sep 202019815
Oct 202027518
Nov 202023715
Dec 202012148
Jan 202181210
Feb 2021181418
Mar 2021131518
Apr 202171320
May 202182330
Jun 202184514
Jul 2021113122
Aug 202181612
Sep 2021121619
Oct 2021123029
Nov 202182417
Dec 202173517
Jan 202216327
Feb 2022131410
Mar 202261811
Apr 202291618
May 2022113521
Jun 2022111718
Jul 20225199
Aug 202261916
Sep 202252314
Oct 202252610
Nov 2022103217
Dec 20226216
Jan 2023193217
Feb 202393221
Mar 202383521
Apr 2023113218
May 2023122210
Jun 202342712
Jul 20237318
Aug 202352711
Sep 2023131416
Oct 20237184
Nov 202362011
Dec 20235314
Jan 202410276
Feb 202432510
Mar 202442738
Apr 2024126023
May 2024125815
Jun 20244327
Jul 202462921
Aug 20245439
Sep 20249268
Oct 202472618
Nov 2024242225
Dec 2024122218
Jan 2025142930
Feb 2025145719
Mar 2025134717
Apr 2025174029
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (6)
Journal of Nuclear Medicine
Vol. 59, Issue 6
June 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How Should the FDA Review Diagnostic Radiopharmaceuticals?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
How Should the FDA Review Diagnostic Radiopharmaceuticals?
Carol S. Marcus
Journal of Nuclear Medicine Jun 2018, 59 (6) 868-870; DOI: 10.2967/jnumed.117.200337

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
How Should the FDA Review Diagnostic Radiopharmaceuticals?
Carol S. Marcus
Journal of Nuclear Medicine Jun 2018, 59 (6) 868-870; DOI: 10.2967/jnumed.117.200337
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • HISTORY
    • PROPOSED SOLUTIONS AND CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Perspective on How the FDA Should Review Diagnostic Radiopharmaceuticals
  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • SNMMI Clinical Trials Network Research Series for Technologists: Introduction
  • Perspective on How the FDA Should Review Diagnostic Radiopharmaceuticals
  • Google Scholar

More in this TOC Section

  • Facilitating the End of the Linear No-Threshold Model Era
  • The Future of Nuclear Medicine in the United States
  • Scientific Fraud, Publication Bias, and Honorary Authorship in Nuclear Medicine
Show more Issues and Controversies

Similar Articles

Keywords

  • diagnostic radiopharmaceutical regulation
  • FDA regulation
  • diagnostic radiopharmaceutical advisory committee
SNMMI

© 2025 SNMMI

Powered by HighWire